Yuflyma, A High Concentration and Citrate-free Adalimumab Biosimilar, Received FDA Approval for Treating Different Forms of Inflammato ry Diseases.

Autor: Rajana VK; Department of Biotechnology, National Institute of Pharmaceutical Education and Research, Hajipur, 844102, India., Penumaka SM; Department of Biotechnology, National Institute of Pharmaceutical Education and Research, Hajipur, 844102, India., Saritha C; Department of Biotechnology, National Institute of Pharmaceutical Education and Research, Hajipur, 844102, India., Ravichandiran V; Department of Natural Products, National Institute of Pharmaceutical Education and Research, Kolkata, 700054, India., Mandal D; Department of Biotechnology, National Institute of Pharmaceutical Education and Research, Hajipur, 844102, India.
Jazyk: angličtina
Zdroj: Anti-inflammatory & anti-allergy agents in medicinal chemistry [Antiinflamm Antiallergy Agents Med Chem] 2023; Vol. 22 (4), pp. 273-275.
DOI: 10.2174/0118715230273701231102100558
Databáze: MEDLINE